UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2172-12
Program Prior Authorization/Medical Necessity
Medications *Nucala® (mepolizumab)
* This program applies to the prefilled autoinjector and prefilled syringe
formulations.
P&T Approval Date 8/2019, 4/2020, 8/2020, 3/2021, 6/2021, 9/2021, 11/2021, 2/2022,
6/2022, 6/2023, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Nucala (mepolizumab) is an interleukin-5 receptor antagonist indicated for add-on maintenance
treatment of patients aged 6 years and older with severe asthma and with an eosinophilic
phenotype, for add-on maintenance treatment of adult patients 18 years and older with chronic
rhinosinusitis with nasal polyps (CRSwNP), the treatment of adult patients with eosinophilic
granulomatosis with polyangiitis (EGPA), and the treatment of adult and pediatric patients aged
12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable
non-hematologic secondary cause1.
Limitations of use:
Nucala is not for relief of acute bronchospasm of status asthmaticus.
2. Coverage Criteriaa:
A. Eosinophilic granulomatosis with polyangiitis (EGPA)
1. Initial Authorization
a. Nucala will be approved based on one of the following criteria:
(1) All of the following:
(a) Patient has been established on therapy with Nucala under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
EGPA
-AND-
(b) Documentation of positive clinical response to Nucala therapy as
demonstrated by at least one of the following:
i. Reduction in the frequency and/or severity of relapses
ii. Reduction or discontinuation of doses of corticosteroids and/or
immunosuppressant
iii. Disease remission
iv. Reduction in severity or frequency of EGPA-related symptoms
-AND-
© 2024 UnitedHealthcare Services, Inc.
1
(c) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(d) Prescribed by one of the following:
i. Pulmonologist
ii. Rheumatologist
iii. Allergist
iv. Immunologist
-OR-
(2) All of the following:
(a) Diagnosis of relapsing or refractory EGPA as defined by all of the
following:
i. Diagnosis of EGPA
-AND-
ii. Past medical history or presence of asthma
-AND-
iii. Presence of at least two of the following characteristics typical of
EGPA:
• Histopathological evidence of:
 Eosiophilic vasculitis
 Pervascular eosinophilic infiltration
 Eosinophil-rich granulomatous inflammation
• Neuropathy, mono or poly (motor deficit or nerve
conductionabnormality)
• Pulmonary infiltrates, non-fixed
• Sino-nasal abnormality
• Cardiomyopathy (established by echocardiography or MRI)
• Glomerulonephritis (hematuria, red cell casts, proteinuria)
• Alveolar hemorrhage
• Palpable purpura
• Anti-neutrophil cytoplasmic antibody (ANCA) positive
© 2024 UnitedHealthcare Services, Inc.
2
-AND-
iv. History of relapsing or refractory disease defined as one of the
following:
• Relapsing disease as defined as a past history (within the past 2
years) of at least one EGPA relapse (requiring additional or dose
escalation of corticosteroids or immunosuppressant, or
hospitalization)
• Refractory disease as defined as failure to attain remission within
the prior 6 months following induction treatment with standard
therapy regimens
-AND-
(b) Patient is currently taking standard therapy [i.e., systemic glucocorticoids (e.g.,
prednisone, methylprednisolone) with or without immunosuppressive therapy
(e.g., cyclophosphamide, rituximab)]
-AND-
(c) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab),
Fasenra(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(d) Prescribed by one of the following:
i. Pulmonologist
ii. Rheumatologist
iii. Allergist
iv. Immunologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Nucala will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Nucala therapy as demonstrated
by at least one of the following:
(a) Reduction in the frequency and/or severity of relapses
(b) Reduction or discontinuation of doses of corticosteroids and/or
immunosuppressant
© 2024 UnitedHealthcare Services, Inc.
3
(c) Disease remission
(d) Reduction in severity or frequency of EGPA-related symptoms
-AND-
(2) Patient is not receiving Nucala in combination with any of the following:
(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
B. Severe Asthma
1. Initial Authorization
a. Nucala will be approved based on one of the following criteria:
(1) All of the following:
(a) Patient has been established on therapy with Nucala under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
severe asthma
-AND-
(b) Documentation of positive clinical response to Nucala therapy as
demonstrated by at least one of the following:
i. Reduction in the frequency of exacerbations
ii. Decreased utilization of rescue medications
iii. Increase in percent predicted FEV1 from pretreatment baseline
iv. Reduction in severity or frequency of asthma-related symptoms
(e.g., wheezing, shortness of breath, coughing, etc.)
v. Reduction in oral corticosteroid requirements
-AND-
(c) Nucala is being used in combination with an inhaled corticosteroid (ICS)-
containing maintenance medication [e.g., Advair/AirDuo
(fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol),
Symbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone
furoate/umeclidinium/vilanterol)].
-AND-
© 2024 UnitedHealthcare Services, Inc.
4
(d) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE-therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(e) Prescribed by one of the following:
i. Pulmonologist
ii. Allergist
iii. Immunologist
-OR-
(2) All of the following:
(a) Diagnosis of severe asthma
-AND-
(b) Classification of asthma as uncontrolled or inadequately controlled as
defined by at least one of the following:
i. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ]
score consistently greater than 1.5 or Asthma Control Test [ACT] score
consistently less than 20)
ii. Two or more bursts of systemic corticosteroids for at least 3 days each
in the previous 12 months
iii. Asthma-related emergency treatment (e.g., emergency room visit,
hospital admission, or unscheduled physician’s office visit for nebulizer
or other urgent treatment)
iv. Airflow limitation (e.g., after appropriate bronchodilator withhold
forced expiratory volume in 1 second [FEV1] less than 80% predicted
[in the face of reduced FEV1/forced vital capacity [FVC] defined as
less than the lower limit of normal])
v. Patient is currently dependent on oral corticosteroids for the treatment
of asthma
-AND-
(c) Submission of medical records (e.g., chart notes, laboratory values, etc.)
confirming asthma is an eosinophilic phenotype as defined by a baseline
(pre-treatment) peripheral blood eosinophil level ≥ 150 cells/μL
© 2024 UnitedHealthcare Services, Inc.
5
-AND-
(d) Nucala will be used in combination with one of the following:
i. One maximally dosed (appropriately adjusted for age) combination
inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) [e.g.,
2
Advair/AirDuo Respiclick (fluticasone propionate/salmeterol),
Symbicort (budesonide/formoterol), Breo Ellipta (fluticasone
furoate/vilanterol)]
-OR-
ii. Combination therapy including both of the following:
• One maximally dosed (appropriately adjusted for age) ICS
product [e.g., ciclesonide (Alvesco), mometasone furoate
(Asmanex), beclomethasone dipropionate (QVAR)]
-AND-
• One additional asthma controller medication [e.g., LABA -
olodaterol (Striverdi) or indacaterol (Arcapta); leukotriene
receptor antagonist – montelukast (Singulair); theophylline]
-AND-
(e) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(f) Prescribed by one of the following:
i. Allergist
ii. Immunologist
iii. Pulmonologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Nucala will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Nucala therapy as demonstrated
© 2024 UnitedHealthcare Services, Inc.
6
by at least one of the following:
(a) Reduction in the frequency of exacerbations
(b) Decreased utilization of rescue medications
(c) Increase in percent predicted FEV1 from pretreatment baseline
(d) Reduction in severity or frequency of asthma-related symptoms (e.g.,
wheezing, shortness of breath, coughing, etc.)
(e) Reduction in oral corticosteroid requirements
-AND-
(2) Nucala is being used in combination with an ICS-containing maintenance
medication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta
(fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy
Ellipta (fluticasone furoate/umeclidinium/vilanterol)].
-AND-
(3) Patient is not receiving Nucala in combination with any of the following:
(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
C. Hypereosinophilic Sydrome (HES)
1. Initial Authorization
a. Nucala will be approved based on one of the following criteria:
(1) All of the following:
(a) Patient has been established on therapy with Nucala under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
HES
-AND-
(b) Documentation of positive clinical response to Nucala therapy as
demonstrated by at least one of the following:
i. Reduction in frequency of HES flares
ii. Maintenance or reduction in background HES therapy requirements
-AND-
© 2024 UnitedHealthcare Services, Inc.
7
(c) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(d) Prescribed by one of the following:
i. Allergist
ii. Immunologist
iii. Hematologist
iv. Cardiologist
v. Pulmonologist
-OR-
(2) All of the following:
(a) Diagnosis of HES ≥ 6 months ago
-AND-
(b) Both of the following:
i. There is no identifiable non-hematologic secondary cause of the
patient’s HES (e.g., drug hypersensitivity, parasitic helminth
infection, HIV infection, non-hematologic malignancy)
-AND-
ii. HES is not FIP1L1-PDGFRα kinase-positive
-AND-
(c) Submission of medical records (e.g., chart notes, laboratory values, etc.)
documenting both of the following:
i. Baseline (pre-mepolizumab treatment) blood eosinophil level ≥1000
cells/µL within the past 4 weeks
-AND-
ii. Patient is currently receiving a stable dose of background HES therapy
(e.g., oral corticosteroid, immunosuppressor, or cytotoxic therapy)
© 2024 UnitedHealthcare Services, Inc.
8
-AND-
(d) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(e) Prescribed by one of the following:
i. Allergist
ii. Immunologist
iii. Hematologist
iv. Cardiologist
v. Pulmonologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Nucala will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Nucala therapy as demonstrated
by at least one of the following:
i. Reduction in frequency of HES flares
ii. Maintenance or reduction in background HES therapy requirements
-AND-
(2) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
D. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
1. Initial Authorization
© 2024 UnitedHealthcare Services, Inc.
9
a. Nucala will be approved based on one of the following criteria:
(1) All of the following:
(a) Patient has been established on therapy with Nucala under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
CRSwNP
-AND-
(b) Documentation of positive clinical response to Nucala therapy
-AND-
(c) Patient will continue to receive Nucala as add-on maintenance therapy in
combination with intranasal corticosteroids (e.g., fluticasone, mometasone,
triamcinolone).
-AND-
(d) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
-AND-
(e) Prescribed by one of the following:
i. Allergist
ii. Immunologist
iii. Otolaryngologist
iv. Pulmonologist
-OR-
(2) All of the following:
(a) Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) defined by
all of the following:
i. Two or more of the following symptoms for longer than 12 weeks
duration:
• Nasal mucopurulent discharge
• Nasal obstruction, blockage, or congestion
© 2024 UnitedHealthcare Services, Inc.
10
• Facial pain, pressure, and/or fullness
• Reduction or loss of sense of smell
-AND-
ii. One of the following findings using nasal endoscopy and/or sinus
computed tomography (CT):
• Purulent mucus or edema in the middle meatus or ethmoid
regions
• Polyps in the nasal cavity or the middle meatus
• Radiographic imaging demonstrating mucosal thickening or
partial or complete opacification of paranasal sinuses
-AND-
iii. One of the following:
• Presence of bilateral nasal polyposis
• Patient has previously required surgical removal of bilateral
nasal polyps
-AND-
iv. One of the following:
• Patient has required prior sinus surgery
• Patient has required systemic corticosteroids (e.g., prednisone,
methylprednisolone) for CRSwNP in the previous 2 years
• Patient has been unable to obtain symptom relief after trial of
two of the following classes of agents:
Nasal saline irrigations
o
Intranasal corticosteroids (e.g., fluticasone, mometasone,
o
triamcinolone)
Antileukotriene agents (e.g., montelukast, zafirlukast,
o
zileuton)
-AND-
(b) Patient will receive Nucala as add-on maintenance therapy in combination
with intranasal corticosteroids (e.g., fluticasone, mometasone,
triamcinolone)
-AND-
(c) Patient is not receiving Nucala in combination with any of the following:
i. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
ii. Anti-IgE therapy [e.g., Xolair (omalizumab)]
iii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]
iv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
© 2024 UnitedHealthcare Services, Inc.
11
-AND-
(d) Prescribed by one of the following:
i. Allergist
ii. Immunologist
iii. Otolaryngologist
iv. Pulmonologist
Authorization will be issued for 12 months.
2. Reauthorization
a. Nucala will be approved based on all of the following criterion:
(1) Documentation of positive clinical response to Nucala therapy
-AND-
(2) Patient will continue to receive Nucala as add-on maintenance therapy in
combination with intranasal corticosteroids (e.g., fluticasone, mometasone,
triamcinolone).
-AND-
(3) Patient is not receiving Nucala in combination with any of the following:
(a) Anti-interleukin-5 therapy [e.g., Cinqair (resilizumab), Fasenra
(benralizumab)]
(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]
(c) Anti-interleukin-4 therapy [e.g., Dupixent (dupilumab)]
(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire
(tezepelumab)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limitations may be in place.
• Medical Necessity may be in place.
• The single-dose vial is typically covered under the medical benefit. Please refer to the United
Healthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®, Fasenra®, and
Nucala®)”.
© 2024 UnitedHealthcare Services, Inc.
12
4. References:
1. Nucala® [package insert]. Philadelphia, PA: GlaxoSmithKline, LLC; March 2023.
2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition,
evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb:43(2):343-73.
3. Institute for Clinical and Economic Review (ICER). Mepolizumab (Nucala®, GlaxoSmithKline
plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value-
Based Price Benchmarks. March 14, 2016. Available at http://icer-review.org/material/asthma-
final-report/. Accessed May 2024.
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023.
Available at http://www.ginasthma.org. Accessed May 29, 2024.
5. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, et al. Oral Glucocorticoid-Sparing Effect of
Mepolizumab in Eosinophilic Asthma. New Eng J Med. 2014 Sept:371(13):1189-97.
6. Parameswaran KN, Dasgupta A, et al. Mepolizumab in COPD with Eosinophilic Bronchitis: A
Randomized Clinical Trial. Poster session presented at the Annual Meeting of the American
Academy of Allergy, Asthma and Immunology, Los Angeles, CA. March 2016.
7. Centers for Disease Control and Prevention. Asthma. Available at http://www.cdc.gov./asthma/.
Accessed May 29, 2024.
8. National Heart, Lung and Blood Institute. Explore Asthma. Available at
http://www.nhlbi.nih.gov. Accessed May 29, 2024.
9. Hypereosinophilic Syndrome (HES). American Academy of Allergy, Asthma & Immunology.
Available at https://www.aaaai.org. Accessed May 29, 2024.
10. Roufosse F, Kahn J-E, Rothenberg ME, et. al. Efficacy and safety of mepolizumab in
hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial. Journal of Allergy
and Clinical Immunology. September 2020.
11. Roufosse F, Klion A, Weller P. Hypereosinophilic syndromes: Clinical manifestations,
pathophysiology, and diagnosis. Updated July 22, 2022. Accessed May 29, 2024.
12. Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and
rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6:S22-S209.
13. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice
parameter update. Ann Allergy Asthma Immuno. 2014;113:347-385.
14. Buchheit KM, Holbrook EH.. Chronic rhinosinusitis with nasal polyposis: Management and
prognosis. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Updated
August 3, 2023. Accessed on May 29, 2024.
15. Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N,
Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Apr 16:S2213-2600(21)00097-
7. doi: 10.1016/S2213-2600(21)00097-7. Epub ahead of print. PMID: 33872587.
16. Holbrook EH. Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis.
UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Updated August 3, 2023.
Accessed on May 29, 2024.
© 2024 UnitedHealthcare Services, Inc.
13
17. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the
classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum.
1990;33(8):1094-1100. doi:10.1002/art.1780330806
18. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L,
Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T,
Adcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A,
Djukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H,
Vitary C, Bush A. Management of severe asthma: a European Respiratory Society/American
Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:
10.1183/13993003.00588-2019. PMID: 31558662
Program Prior Authorization/Notification - Nucala (mepolizumab)
Change Control
8/2019 New program.
4/2020 Updated program to address specific product formulations. Updated
references.
8/2020 Annual review. Updated background and references.
3/2021 Updated program to add HES indication. Added limitations of use.
Updated references.
6/2021 Added criteria if patient has been approved and received initial dose of
Nucala directly monitored by a healthcare professional without reaction.
9/2021 Added coverage criteria for new indication, chronic rhinosinusitis with
nasal polyps. Updated background and references.
11/2021 Added coverage criteria for patients established on therapy under
UnitedHealthcare medical benefit. Removed prescriber requirement for
reauthorization.
2/2022 Added Tezspire to list of agents not to be used in combination with
Nucala for all indications. Updated coverage criteria for CRSwNP.
Updated references. Added footnote to support FDA labeled first line
requirements.
6/2022 Added pulmonologist to list of appropriate prescribers in section for
patients established on therapy with Nucala for CRSwNP.
6/2023 Annual review. Updated examples of standard therapy for EGPA and
added examples of oral corticosteroids within Asthma criteria. Updated
background and references.
7/2023 Updated EGPA standard therapy examples. Updated coverage criteria
for severe asthma to align with GINA & ERS/ATS guidelines.
Added/updated examples of ICS-containing maintenance medications,
removed requirement that peripheral blood eosinophil level must be
within 6 weeks, and removed bypass of eosinophilic phenotype
requirement for patients currently dependent on maintenance therapy
with oral corticosteroids. Updated references.
7/2024 Annual review. Updated background with modified indication for
CRSwNP. Specified existing prior authorization for under the medical
benefit. Updated references.
© 2024 UnitedHealthcare Services, Inc.
14